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More than one-fifth of ovarian tumors have hereditary susceptibility and, in about 65–85% of these cases, the genetic abnormality
is a germline mutation in BRCA genes. Nevertheless, several other suppressor genes and oncogenes have been associated with
hereditary ovarian cancers, including the mismatch repair (MMR) genes in Lynch syndrome, the tumor suppressor gene, TP53, in
the Li-Fraumeni syndrome, and several other genes involved in the double-strand breaks repair system, such as CHEK2, RAD51,
BRIP1, and PALB2. The study of genetic discriminators and deregulated pathways involved in hereditary ovarian syndromes is
relevant for the future development ofmolecular diagnostic strategies and targeted therapeutic approaches.The recent development
and implementation of next-generation sequencing technologies have provided the opportunity to simultaneously analyzemultiple
cancer susceptibility genes, reduce the delay and costs, and optimize the molecular diagnosis of hereditary tumors. Particularly, the
identification of mutations in ovarian cancer susceptibility genes in healthy women may result in a more personalized cancer risk
management with tailored clinical and radiological surveillance, chemopreventive approaches, and/or prophylactic surgeries. On
the other hand, for ovarian cancer patients, the identification of mutations may provide potential targets for biologic agents and
guide treatment decision-making.
1. Introduction
Ovarian cancer represents the leading cause of cancer deaths
among gynecological malignancies, accounting worldwide
for about 225.000 new cancer cases (3.7% of all female
cancers) and about 140,000 deaths (4.2% of all deaths in
women) every year [1]. In the United States, 21,980 estimated
new cases and 14,270 estimated deaths were expected in 2014
[2]. The lack of effective early detection strategies and an
unfavorable anatomy are associated with the advanced stage
at diagnosis and poor prognosis often found in ovarian cancer
patients. Therefore, overall survival (OS) is the worst among
all of the gynecologic malignancies, with a five-year relative
survival rate of 44% for all stages in all races [2].
More than one-fifth (about 23%) of ovarian carcinomas
have been related to hereditary conditions [3]. Particularly,
in about 65–85% of hereditary ovarian tumors, the genetic
abnormality is a germline mutation in BRCA genes that
causes DNA repair defects. BRCA1 and BRCA2 mutation
carriers have an increased lifetime risk of developing breast
and ovarian cancer (up to 85% for breast cancer and up to
54% for ovarian cancer), as well as pancreatic and prostate
cancer [4–8]. Nevertheless, several other suppressor genes
and oncogenes have been associated with hereditary ovarian
cancer (i.e., TP53, BARD1, CHEK2, RAD51, and PALB2 [3, 9–
11]). To date, at least 16 genes are known to be involved in the
mechanism of hereditary ovarian tumorigenesis and several
other mutations remain unknown and cannot be detected by
specific tests [12] (Figure 1).
The identification of amutation in ovarian cancer suscep-
tibility genes represents a fundamental step in the diagnosis
and treatment of these tumors. First of all, the detection
of a specific mutated gene in healthy women may jus-
tify more intensive and personalized surveillance programs,
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Figure 1: Susceptibility genes and their prevalence in hereditary
ovarian syndromes.
chemopreventive approaches, and/or prophylactic surgery
that would not otherwise be justified by family history
alone. Moreover, the identification of a mutation in already
affected patients may provide fundamental knowledge of the
pathogenesis of their tumors. Therefore, this genetic evalu-
ation at diagnosis may help to identify potential targets for
specific drugs, that is, PARP inhibitors and alkylating agents,
and to guide decision-making on treatment strategies. In
this context, next-generation sequencing (NGS) technologies
have recently provided an unprecedented opportunity to
simultaneously analyze multiple cancer susceptibility genes,
reduce delays and costs, and optimize the molecular diagno-
sis of hereditary ovarian cancer.
We reviewed the available published data regarding the
molecular pathways involved in the pathogenesis of non-
BRCAhereditary ovarian cancer and the possible applications
of NGS technologies in these hereditary cancer syndromes.
2. Clinical, Histopathological, and Molecular
Features of Ovarian Cancer
Ovarian cancer is a heterogeneous disease that includes
different biological behaviors at the clinical and molecular
level. More than 90% of ovarian cancers are epithelial, while
about 10% of ovarian cancers develop from germ cells or
granulosa-theca cells. Epithelial tumors may arise from the
ovarian surface epithelium but also may arise from fallopian
tube, foci of endometriosis, or the peritoneum [13]. Fourmain
histotypes characterize epithelial ovarian cancer: serous,
endometrioid, mucinous, and clear cell. Interestingly, each
histotype shows patterns of gene expression that correlate
Table 1: Different types of ovarian cancer with their clinicopatho-
logic features and behavior.
Type 1 Type 2
Prevalence About 30% About 70%
Histotype
Serous, endometrioid,
mucinous, and
clear-cell tumors
Serous, mixed
malignant
mesodermal tumors
carcinosarcomas,
and undifferentiated
tumors
Grade Low and borderline High
Mutations
PTEN, KRAS, BRAF,
PIK3CA, ERBB2,
CTNNB1, ARID1A,
PPP2R1A, and
microsatellite
instability
TP53
BRCA 1/2
Clinical behavior
Typically large cystic
mass confined to the
ovary, relatively
indolent course
Diagnosed at
advanced stages and
aggressive behavior
with their morphological counterparts in normal tissues.
Particularly, alterations in serous tumors correlated with
those in normal fallopian tube, mucinous cancers correlated
with those in normal colonicmucosa, and both endometrioid
and clear cell histotypes correlated with changes in normal
endometrium [14].
Two novel hypotheses for the pathogenesis of serous
ovarian cancer have been recently proposed. According to
the first mechanism, precursors of ovarian cancer develop in
the fimbria fromoccult serous tubal intraepithelial carcinoma
(STIC), and only subsequently do they involve the ovary.
The second theory supports the implantation of normal
epithelium from the fimbria onto the ovarian surface during
ovulation, which results in a cortical inclusion cyst (CICs)
where malignant transformation can arise [15, 16].
At the molecular level, sporadic ovarian cancer is charac-
terized by wide genetic instability linked to themodulation of
several genes. According to clinical behavior and the molec-
ular genetic abnormalities, ovarian cancer can be classified
into two different types (Table 1). Type I tumors include
low-grade serous carcinomas, borderline serous tumors, low-
grade endometrioid, andmucinous and clear-cell carcinomas
[15, 17]. These kinds of tumors are relatively genetically
stable, and themost frequentmutations involveKRAS,BRAF,
ERBB2, PTEN, PIK3CA, b-catenin gene (CTNNB1), ARID1A,
and PPP2R1A. On the other hand, type II ovarian cancers
include high-grade serous carcinomas, carcinosarcomas, and
undifferentiated cancers. Type II tumors, which comprise
almost 70%of all epithelial tumors, are aggressive and present
in advanced stages. At the time of presentation, they exhibit
high genomic instability and, in up to 95% of patients,
the gene mutated is TP53. Moreover, this type of tumor is
characteristic of BRCA1 and BRCA2 mutation carriers and
mostly arises from STICs [15, 17].
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Figure 2: Type of DNA damage, repair pathways, and repair enzymes involved in each pathway.
3. Mismatch Repair Genes and
Lynch Syndrome
In the mid1960s, Lynch and colleagues described an
autosomal-dominant hereditary syndrome that predisposes
young people (mean age 45 years) not affected by
adenomatous colonic polyps, to develop colorectal cancer
with predilection proximal to the splenic flexure [18, 19].
Subsequent publications on the syndrome reported that
members of these families were also prone to excesses
of extracolonic cancers, including carcinomas of the
endometrium, ovary, stomach, small bowel, hepatobiliary
tract, pancreas, renal pelvis, ureter, breast, prostate, and brain
(particularly glioblastomas) [20–22].
Lynch syndrome (LS), also known as hereditary non-
polyposis colon cancer (HNPCC), accounts for 10–15% of
all hereditary ovarian cancers [23]. The cumulative lifetime
risk of ovarian cancer is estimated to be 6–10% in proven or
probableMSH2 andMLH1mutation carriers, with an average
age of onset of 51 years in families associated with MLH1
mutations and 45 years in families associated with MSH2
mutations [24–26]. From the clinical point of view, ovarian
cancers in LS are mostly endometrioid or clear cell [27–31],
and the tumors are less advanced at the time of diagnosis,
showing strikingly high stage-specific survival rates [24, 32,
33]. In particular, Vierkoetter and coinvestigators found that
patients under the age of 53 with clear cell or endometrioid
ovarian carcinomas are at a clinically significant risk for loss
of mismatch repair (MMR) expression and LS, suggesting
that routine screeningwith immunohistochemical staining in
these patients should be considered [34].
LS is determined by germline mutations in MMR genes
(MLH1, MSH2, MSH6, MLH3, and PMS2), which lead
to the loss of expression of one of the MMR proteins.
In LS, one mutated allele of an MMR gene is inherited,
and the loss of the second allele occurs somatically, due
to mutation, methylation, or a combination of both. The
rare case where both inherited alleles are mutated is called
“the constitutional MMR deficiency syndrome” and leads to
cancer during childhood [35]. The mismatch repair (MMR)
system, together with the base excision repair (BER) and the
nucleic acid excision repair (NER) system, is the DNA repair
mechanism employed to remove single-strand breaks. On
the other hand, double-strand breaks are corrected by the
homologous recombination (HR) and nonhomologous end
joining (NHEJ) (Figure 2) [8]. Failure of the MMR system,
which occurs in families with LS, results in the accumulation
of repeated nucleotide sequences phenotypically expressed
as microsatellite instability (MSI). Microsatellites are short
tandem (1–6 base pairs) repeated DNA sequences with high
susceptibility for replication errors. Several oncogenes and
tumor suppressor genes contain microsatellites, including
TGF𝛽R2, IGFIIR, BAX, and DNA double-strand break (DSB)
repair genes, such as Mre11 and RAD50. Consequently,
impairment of MMR could cause mutations in many genes
implicated in tumorigenesis [36–40].
Nevertheless, carcinogenesis in ovarian cancers associ-
ated with LS has not been completely explained beyond
the description of MMR defects. Recently, Niskakoski and
colleagues [41] investigated 107 ovarian tumors (20 from
LS and 87 sporadic), in order to gain insights into ovarian
tumorigenesis and to analyzemolecular alterations that differ
between LS and sporadic ovarian cancer. As previously
described, LS-associated ovarian cancers were more likely
at diagnosis to be of low-grade, early stage, early onset and
generally had an overall better prognosis. All 20 LS-associated
ovarian carcinomas did not show mutations on TP53, KRAS
(exon 2), or BRAF (V600E), while, in sporadic ovarian
carcinomas, TP53 was often abnormal (overexpressed or
completely missing) and KRAS (exon 2) mutations occurred
with a frequency of 8%. In fact, overexpression of TP53 in
ovarian cancer has been linked with poor prognosis, high
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grade histology, and advanced stages at diagnosis [42]. Inter-
estingly, the frequencies of PIK3CA mutations were similar
in endometrioid and clear cell carcinomas from LS patients
(32%) compared to their sporadic counterparts (36%). The
frequency of PIK3CA mutations in LS-associated ovarian
carcinomas is in accordance with the reported high survival,
since recent evidence suggests that PIK3CA mutations and
the PI3K/AKT pathway activation are associated with a
favorable prognosis in ovarian cancer [43].These data showed
that ovarian cancers seem to resemble colorectal cancers from
LS carriers, which are associated with higher stage-specific
survival [44] and fewer TP53 and BRAF abnormalities
compared to sporadic tumors [45] and PIK3CA mutations
in about 20% of cases [46]. Furthermore, Niskakoski and
colleagues [41] found differences in the analysis of cyclin-
dependent kinase inhibitor 2B (CDKN2B) and long inter-
spersed nucleotide element 1 (LINE1). Hypomethylation of
CDKN2B and LINE1 was significantly increased in sporadic
ovarian cancers compared with LS cases. Since LINE1 plays
an important role in advanced stages of ovarian cancer, this
result is consistent with better prognosis showed by LS-
associated ovarian cancer [47].
More recently, Jo¨nsson and colleagues [48] performed
a global gene expression analysis on 24 LS-associated and
24 sporadic ovarian tumors, with the aim of identifying
gene expression profiles and genetic discriminators asso-
ciated with LS. The most frequently upregulated genes in
LS included PTPRH, BIRC3, SHH, and TNFRSF6B. The
genes involved were predominantly related to cell growth,
proliferation, and cell-to-cell signaling and interaction. On
the other hand, immunohistochemical staining showed pos-
itivity for p-mTOR in 60% of LS tumors, EGFR in 30%
of LS tumors, and loss of PTEN in 74% of LS tumors.
Moreover, mutations inKRAS and BRAF, whichmay activate
the mTOR/PI3K/AKT pathway, are common in low-grade
ovarian cancers (60%) [49, 50].
The study of genetic discriminators and deregulated
pathways involved in LS-associated ovarian tumorigenesis
may be relevant for the future development of molecular
diagnostics and targeted therapeutics. Unfortunately, given
the relative rarity of LS-associated hereditary ovarian cancer,
the sample sizes in these studies were small and confirmation
in a larger series is necessary. Moreover, other common
limitations of these studies may be related to the techniques
used for the analyses, including immunohistochemistry and
genetic testing on paraffin-embedded tumor tissues.
4. TP53 and Li-Fraumeni Syndrome
The Li-Fraumeni syndrome (LFS) is an autosomal domi-
nant cancer syndrome determined by heterozygous germline
mutations in the tumor suppressor gene TP53 (chromosome
17p13). TP53 codes for a transcription factor activated in
response to various stress signals and implicated in cell
proliferation, apoptosis, and genomic stability. It represents
the most frequently mutated gene in human cancer, with the
highest prevalence of acquiredmutations in epithelial ovarian
(47%), colorectal (43%), head/neck (42%), and esophageal
(41%) cancers [51, 52]. Because of its comprehensive role as a
cancer suppressor gene, TP53 is also defined as the “guardian
of the genome” [53].Themost commonmutation observed in
germline and sporadic cases is the missense mutation (about
75%), resulting in a defective transcriptional activity. Tumors
developed from acquired TP53 mutations are characterized
by worse survival rates, increased resistance to chemotherapy
and radiation, and elevated relapse rates [54–56].
Li and Fraumeni Jr. proposed for the first time in 1969 the
theory of a hereditary cancer syndrome characterized by the
early development ofmultiple tumors [57]. Particularly, about
50% of patients with LFS develop the first tumor by age of 30
[58, 59], and almost one-third (15–35%) of them will develop
multiple primary cancers over their lifetimes [60, 61]. Breast
cancer, sarcoma and brain, and adrenocortical carcinoma
represent about 77–80% of LFS-associated tumors. Less
frequent malignancies associated with LS include leukemia
and lung, colorectal, skin, gastric, and ovarian cancer and
these account for 15% of the tumors [62]. Nevertheless, these
less frequent tumors are present in the general population;
thus, their presence in LFS families could be because of
chance. On the other hand, in the context of a germline TP53
mutation, these tumors occur at earlier than expectedmedian
age at diagnosis. Particularly, for ovarian cancer the median
age is 39.5, compared with 64.3 years for sporadic cases
[63].The lack of comprehensive studies regarding the genetic
pathways involved in LFS-associated ovarian tumorigenesis
is principally due to the extreme rarity of this syndrome in
the general population.
5. Genes Involved in Double-Strand
Breaks Repair
As previously described, double-strand breaks (DSBs) are
repaired by homologous recombination (HR) and non-
homologous end joining (NHEJ) (Figure 2). HR provides
accurate recombination using a sister chromatid as a tem-
plate which maintains genomic stability. Several proteins
are widely involved in the HR system, including BRCA1/2,
ATM, CHEK2, RAD51, and Fanconi anemia proteins (BRIP1
[64] and PALB2 [65]) (Figure 3) [66]. Particularly, DSBs
activate the kinases ATM, ATR, and CHEK2, which in turn
phosphorylate BRCA1, modulating its function. The role of
BRCA1 in DNA repair and in cell cycle regulation is to cause
G1-S, S, or G2-M phase arrest depending on the residues
phosphorylated. BRCA1 forms a complex with BARD1, a pro-
tein with structural similarity, which is important for BRCA1
stability. More recently, the BRCA1-BARD1 complex has been
found to play a role in ubiquitination and degradation of RNA
polymerase II, inhibiting transcription and RNA processing,
in order to eliminate prematurely terminated transcripts and
clear the damaged DNA region for the intervention of DNA
repair enzymes. In parallel, BRCA2 participates in the repair
of DSBs modulating the recombinase function of RAD51.
BRCA2 is necessary for the transport of RAD51 into the
nucleus and to the site of DNA damage, where RAD51 is
released to form the nucleoprotein filament required for
recombination [67–69].
On the other hand, although less accurate, NHEJ plays a
crucial role in minimizing DNA damage in both G0 and G1
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Figure 3: Proteins involved in the homologous recombination (HR) system.
phases of the cell cycle, when HR cannot be supplied. How-
ever, when a defect occurs in one of the enzymes involved
in HR, the DSBs are repaired by error prone mechanisms,
mostly NHEJ, resulting in an increased risk of new chromo-
somal defects, and, therefore, the development of cancer [70].
In the first step of NHEJ, the heterodimer Ku70/Ku80 breaks
the DNA ends and improves the stability of the NHEJ related
enzymes at the DNA termini. Two Ku70/Ku80 heterodimers
recruit DNA-dependent protein kinases (DNA-PKcs) to the
DNA ends. The resulting complex of DNA-PKcs and its
substrate, Artemis, have shown an endonuclease activity;
therefore, it processes the DNA termini in order to prepare
them for the intervention of XRCC4-Ligase IV. The nuclease
functions ofArtemis seem to be accomplished by the complex
of RAD50, Mre11, and NBS1, where in vitro models have
shown to interact also with Ligase IV and Ku homologues
(Figure 4) [71].
As mentioned above, several proteins interact and coop-
erate with BRCA1 and BRCA2 proteins in the DNA repair
process, and, therefore, in the maintenance of genomic
stability. It has been hypothesized that genes coding for
these proteins would be alternative candidates for ovarian
cancer susceptibility. Particularly, tumors with a defect in the
HR system other than BRCA express the BRCAness profile.
These tumors present a specific phenotype with features and
behavior similar to BRCA-related ovarian cancers [8], includ-
ing sensitivity to DNA-damaging agents (i.e., platinum),
improved disease-free intervals and survival rates, and high-
grade serous histology [72, 73]. Interestingly, these BRCAness
patients are at increased risk for both ovarian and breast
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cancers, similar to BRCA carriers.Themain genes involved in
the BRCAness syndrome in ovarian cancer are listed below.
5.1. RAD51. Loveday and colleagues [74] identified truncat-
ing RAD51D mutations in 8 of 911 familial breast-ovarian
cancer pedigrees, demonstrating that RAD51D mutations
confer a sixfold increased risk of ovarian cancer but cause
only a small increase in breast cancer. Similarly, Meindl and
associates [75] analyzed 1,100 German families with gyneco-
logical malignancies and identified 6 monoallelic pathogenic
mutations in RAD51C that confer an increased risk for both
breast and ovarian cancers. Finally, Blanco and colleagues
[76] recently screened a large series of 516 BRCA1/BRCA2-
negative patients from breast and/or ovarian cancer families
for RAD51C mutations and identified 3 germline pathogenic
mutations. These results confirmed that RAD51C contributes
to ovarian cancer susceptibility in families with breast and
ovarian cancer cases.
5.2. PALB2. PALB2mutations have been detected in 1–4% of
families negative for BRCA mutations [77]. Inherited muta-
tions in the BRCA2-interacting protein, PALB2, are known
to be associated with increased risks of breast, pancreatic,
and, likely, ovarian cancer. Recently, Casadei and colleagues
sequenced the coding sequences and flanking regulatory
regions of PALB2 from constitutional genomic DNA of
1,144 familial breast cancer BRCA1/BRCA2-negative patients.
PALB2 heterozygotes were four times more likely to have a
male relative with breast cancer (𝑃 = 0.0003), six times more
likely to have a relative with pancreatic cancer (𝑃 = 0.002),
and 1.3-fold more likely to have a relative with ovarian cancer
(𝑃 = 0.18) [10]. Overall, significantly less ovarian cancer
is seen in PALB2 families when compared with BRCA1 and
BRCA2 families; therefore, it remains to be seen whether
ovarian cancer risk is truly increased in individuals who are
PALB2mutation carriers or not [77].
5.3. CHEK2. Furthermore, several groups have previously
analyzed the role of CHEK2 mutations in ovarian cancer
cancerogenesis. Particularly, the missense variant of CHEK2
I157T was significantly associated with ovarian cystadeno-
mas, borderline ovarian tumors, and low-grade invasive
cancers but not high-grade ovarian cancer [78]. In another
study, Baysal and colleagues [79] identified del1100C and
A252G variants of CHEK2, but since the differences in
variant frequency were not statistically significant compared
to controls, it was concluded that variations in CHEK2
were not associated with ovarian cancer pathogenesis. A
few years later, Krylova and colleagues [80] also failed to
demonstrate an association between CHEK2 1100delC and
ovarian cancer pathogenesis. Nevertheless, these analyses
were mainly focused on some specific variants of CHEK2
(del1100C, A252G, and I157T); therefore, mutations of other
regions of CHEK2 and their association with ovarian cancer
pathogenesis still need to be investigated in detail [81].
5.4. Mre11 Complex. The Mre11 complex is composed of
the proteins Mre11, NBS1, and RAD50 and represents a
crucial component in theDNA repair process. Heikkinen and
colleagues [82] screened 151 families with signs of hereditary
breast and/or ovarian cancer for germline mutations in the
Mre11 complex genes. In this study, three potentially disease-
relatedmutations were reported:Mre11 913C>T (Arg305Trp),
NBS1 448C>T (Leu150Phe), andRAD50 687delT (stop codon
at 234). These three mutations in the Mre11 complex genes
could also potentially be related to hereditary susceptibility
to breast and ovarian cancer.
5.5. BARD1. Ratajska and colleagues [83] screened 109
BRCA1/2 negative high-risk breast and/or ovarian cancer
patients from North-Eastern Poland for BARD1 germline
mutations and identified three different BARD1 variants
suspected to be pathogenic (c.1690C>T, p.Gln564X; c.1315-
2A>G; c.1977A>G). This study suggested that deleterious
mutations in BARD1 might be responsible for a certain
proportion of familial breast and/or ovarian cancer.
6. Next-Generation Sequencing with
Multigene Panels
Approximately 23% of ovarian carcinomas have been related
to hereditary conditions and more than 15% of hereditary
ovarian cancers are derived from a genetic condition unre-
lated to BRCA genes [3]. Particularly, several genes involved
in the mechanism of hereditary ovarian tumorigenesis have
been identified, but several mutations still remain unknown
and cannot be detected by specific tests.
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The identification of mutations in ovarian cancer suscep-
tibility genes has a fundamental role both in the preventive
setting, and after the diagnosis of ovarian cancer, in the
selection of treatments. In healthy mutation carriers, the
presence of one of thesemutationsmay justifymore intensive
surveillance, chemopreventive approaches [84, 85], and/or
prophylactic surgeries [86] that would not otherwise be
justified by family history alone. In this particular setting, the
candidates for genetic testing should be identified according
to their personal and family history of ovarian cancer.
On the other hand, in already affected patients, the
identification of a mutation in susceptibility genes may guide
treatment decision-making by providing potential targets for
biologic agents (i.e., PARP inhibitors) or by helping to select
treatment strategies, that is, avoiding radiotherapy in patients
with LFS [87]. Notably, a subgroup analysis of phase 2 trial
data showed that olaparib maintenance therapy significantly
prolongs PFS in patients with BRCA-mutated ovarian cancer
(median, 11.2 versus 4.3 months; HR 0.18; 95% CI [0.10–
0.31]; 𝑃 < 0.0001) [88]. These results led to the accelerated
approval of the PARP inhibitor, olaparib, by the European
Medicines Agency (EMA) for the maintenance treatment
of patients with platinum-sensitive, relapsed BRCA-mutated,
high-grade serous epithelial ovarian, fallopian tube, or pri-
mary peritoneal cancer.More recently, theUnited States Food
and Drug Administration (FDA) approved olaparib for the
treatment of patients with ovarian cancer who have received
three or more prior regimens and carry BRCA mutations.
These approvals have crucial implications in themanagement
of patients with high-grade serous tumors, which represent
75% of all epithelial ovarian cancers. In the near future,
early and rapid genetic testing should be offered to every
patient with these characteristics in order to provide the best
therapeutic strategies.
Next-generation sequencing (NGS) technologies in
recent years have facilitated an unprecedented capability
to gain a better understanding of the genetic complexity
of epithelial ovarian cancer. NGS technologies, based on
massively parallel sequencing, offer several advantages over
the previous techniques:
(1) To analyze simultaneously multiple cancer suscepti-
bility genes in one reaction.
(2) To reduce the time required to complete the genetic
analyses.
(3) To screen additional loci at low additional costs.
(4) Great sensitivity, specificity, and accuracy.
Today, several multigene panels that include known
ovarian cancer-associated loci have been introduced for the
screening of germline mutations [89–91]. Nevertheless, there
are significant challenges in interpreting andmanaging panel
results. The main disadvantages of NGS techniques are listed
below:
(1) Although the overall cost continues to decrease,
there are relevant initial costs associated with the
technology such as sophisticated computer systems,
bioinformatics tools, training of personnel, and, addi-
tionally, a significant time contribution.
(2) Testing multiple genes simultaneously may identify
an increasing number of variants of uncertain clin-
ical significance (VUS), namely, mutations whose
clinical significance has not yet been determined.
Even for known high-risk genes, such as BRCA1/2,
approximately 13% of families tested carry a “hard to
interpret” variant [92], and this rate is expected to
increase with the introduction of multigene panels
(Figure 5) [93].
(3) For several mutated genes, clinical management is
complex and unclear. For example, LFS is character-
ized by a wide tumor spectrum and tumor risk in
children; therefore, TP53 testing should be carefully
considered and all of the clinical implications of
a positive test should be clearly explained before
testing.
(4) The simultaneous evaluation of multiple genes
requires novel approaches to genetic counseling.
Given the always increasing complexity of testing
and results interpretation, a more articulate post-test
counseling and longer-term clinical management are
necessary.
Due to these challenges in interpreting and managing
multigene panel results, much of this information is con-
tained within the field of research and only in specialized
8 BioMed Research International
centers should become standard of care. Mutational screen-
ing and genetic counseling by NGS should be centralized
and carried on in specialized family cancer clinics, where
patients and their families are appropriately informed of the
limitations of these approaches, and then can be followed
and managed by a multidisciplinary team over an extended
period of time [94].
7. Conclusions
Ovarian cancer represents 3.7% of all female cancers. It is
usually diagnosed in advanced stages with a poor prognosis
and OS being the worst of all gynecologic malignancies [1,
2]. More than one-fifth of ovarian tumors have hereditary
susceptibility [3], and in about 65–85% of cases the genetic
abnormality is a germline mutation in BRCA genes. Never-
theless, several other suppressor genes and oncogenes have
been associated with hereditary ovarian cancers, including
mismatch repair (MMR) genes, TP53, and several genes
involved in double-strand breaks repair. To date, at least
16 genes are known to be involved in the mechanism of
hereditary ovarian tumorigenesis, but several mutations still
remain unknown and cannot be detected by specific tests [12].
Defects in genes involved in the repair of double stranded
breaks, other than BRCA 1 and 2, represent alternative mech-
anisms of hereditary ovarian carcinogenesis. BRCA negative
tumors with a defect in the homologous recombination
system express the BRCAness profile, a specific phenotype
with features and behavior similar to BRCA-related cancers
[8]. It is likely that these patients also might benefit from
platinum-based therapies and/or PARP inhibition like BRCA
mutation carriers do, but, to date, we still need to introduce
validated tests into daily practice in order to identify patients
with “BRCAness” profiles who carry mutations in genes such
as ATM, CHEK2, RAD51, BRIP1, and PALB2.
In recent years, the development and implementation
of NGS technologies have provided the opportunity to
simultaneously analyze multiple cancer susceptibility genes,
significantly increase the throughput, reduce the delay and
costs, and optimize the molecular diagnosis of hereditary
ovarian cancer. The identification of mutations in ovarian
cancer susceptibility genes through multigene panels may
result inmore personalized cancer riskmanagement with tai-
lored clinical and radiological surveillance, chemopreventive
approaches, and/or prophylactic surgeries [84–86]. On the
other hand, for ovarian cancer patients, the identification of
mutations may provide potential targets for biologic agents
and help to guide treatment decision-making. Nevertheless,
since there still are significant challenges in interpreting
and managing panel results, much of this information still
remains within the field of research and only in specialized
centers should become standard of care. More intensive
efforts to organize qualified family cancer clinics where the
mutational screening and genetic counseling by NGS should
be centralized and performed need to occur. Patients and
families withmutations should be informed of the limitations
of these approaches and then should be followed up and
managed by a multidisciplinary team over an extended time
period [94]. The centralization of genetic testing enables
the improvement of access and quality of testing and allows
for the creation of a more comprehensive database for
research, guiding evidence-based management recommen-
dations [89–91].
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